Matthew Cunningham, MD
Family Medicine · Clifton Park, NYNPI 1114988904
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 96.0% of the total across 345 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 33 manufacturers, the largest accounting for just 18.1% — the pattern of someone who eats at a lot of different presentations. Among family medicine clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 345 payments — averaging $18.01 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- Novo Nordisk$915
- AstraZeneca$575
- Astellas Pharma US Inc$417
- Amgen$344
- Lilly USA, LLC$337
- plus $3K from 27 others
Across 32 payments — averaging $5709.37 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Ocular Therapeutix, Inc.$183K
What the payments were for
- Food & beverage$5,96896%
- Education$2464%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 75 | $1,123 |
| Novo Nordisk | 52 | $915 |
| AstraZeneca | 15 | $575 |
| Astellas Pharma US Inc | 13 | $417 |
| Amgen | 22 | $344 |
| Lilly USA, LLC | 16 | $337 |
| Pfizer | 21 | $290 |
| Abbott | 13 | $288 |
| GSK | 16 | $255 |
| Boehringer Ingelheim | 14 | $250 |
| Merck | 14 | $184 |
| Dexcom, Inc. | 8 | $172 |
| Johnson & Johnson | 9 | $122 |
| Otsuka America Pharmaceutical, Inc. | 5 | $113 |
| Phathom Pharmaceuticals, Inc. | 6 | $100 |
| Bayer | 5 | $91 |
| Verona Pharma, Inc. | 3 | $74 |
| Novartis | 5 | $67 |
| Idorsia Pharmaceuticals US Inc | 4 | $66 |
| Sanofi-aventis U.S. LLC | 3 | $64 |
| E.r. Squibb & Sons, L.L.C. | 3 | $59 |
| Teva Pharmaceuticals USA, Inc. | 5 | $58 |
| Sunovion Pharmaceuticals Inc. | 6 | $49 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 1 | $31 |
| Lundbeck LLC | 2 | $30 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $26 |
| Amarin Pharma, Inc. | 1 | $21 |
| Tactile Systems Technology Inc | 1 | $19 |
| Radius Health, Inc. | 1 | $18 |
| Mannkind Corporation | 1 | $17 |
| Kowa Pharmaceuticals America, Inc. | 1 | $14 |
| Amneal Pharmaceuticals LLC | 1 | $13 |
| Alkermes, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$6,214 in reported general payments places this provider in the 90th percentile of 4,321 family medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 151 | $191,339 |
| JardianceEmpagliflozin | 89 | $120,645 |
| FarxigaDapagliflozin Propanediol | 51 | $52,886 |
| EliquisApixaban | 42 | $49,065 |
| JanuviaSitagliptin Phosphate | 34 | $42,433 |
| TrulicityDulaglutide | 18 | $27,406 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 22 | $21,488 |
| TradjentaLinagliptin | 19 | $21,167 |
| XareltoRivaroxaban | 16 | $13,109 |
| TrintellixVortioxetine Hydrobromide | 11 | $6,143 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 30 | $4,540 |
| Levothyroxine Sodium | 302 | $4,339 |
| Novolog FlexpenInsulin Aspart | 20 | $4,117 |
| Aripiprazole | 29 | $3,762 |
| Atorvastatin Calcium | 354 | $3,350 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $915 | $191,339151 claims |
| Boehringer IngelheimJardiance, Tradjenta | $250 | $141,812108 claims |
| AstraZenecaFarxiga | $575 | $52,88651 claims |
| PfizerEliquis | $290 | $49,06542 claims |
| MerckJanuvia | $184 | $42,43334 claims |
| Lilly USA, LLCTrulicity | $337 | $27,40618 claims |
| GSKTrelegy Ellipta | $255 | $21,48822 claims |
| Johnson & JohnsonXarelto | $122 | $13,10916 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $26 | $6,14311 claims |
| Amneal Pharmaceuticals LLCLevothyroxine Sodium | $13 | $4,339302 claims |
| AbbVieSynthroid | $1,123 | $1,73241 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,321 family medicine providers in New York.
Other family medicine in Clifton Park
- Louis BonavitaEast Syracuse$674K
- Martin MahoneyBuffalo$520K
- Scott BrehautClinton$514K
- David St PeterSaratoga Springs$395K
- Matthew PabisNew York$222K
- Rajveer SachdevPomona$211K
- Eric SchnakenbergHalfmoon$190K
- James NorthGlens Falls$186K
- Eric BatesNew York$171K
- Alexander BlinskiNew York$159K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.